is predicted to increase the exposure to trazodone.
▶ Imatinib is predicted to increase the exposure to ulipristal.
Avoid if used for uterine fibroids.oStudy
▶ Imatinib is predicted to increase the exposure to venetoclax.
Avoid or adjust dose—consult product literature.rStudy
▶ Imatinib is predicted to increase the exposure to vinca
alkaloids.rTheoretical → Also see TABLE 15 p. 1378
▶ Imatinib is predicted to increase the exposure to zopiclone.
Imidapril → see ACE inhibitors
Imipramine → see tricyclic antidepressants
Anti-D (Rh0) immunoglobulin . antithymocyte immunoglobulin
immunoglobulin. ▶ Immunoglobulins are predicted to alter the effects of
monoclonal antibodies (dinutuximab). Avoid.rTheoretical
Indacaterol → see beta2 agonists
Indapamide → see thiazide diuretics
Indoramin → see alpha blockers
Infliximab → see monoclonal antibodies
Influenza vaccine (live) → see live vaccines
Inotersen → see TABLE 4 p. 1375 (antiplatelet effects)
Inotuzumab ozogamicin → see monoclonal antibodies
Insulins → see TABLE 14 p. 1378 (antidiabetic drugs)
▶ Fibrates are predicted to increase the risk of hypoglycaemia
when given with insulins.oTheoretical
Interferon alfa → see interferons
Interferon beta → see interferons
Interferons → see TABLE 15 p. 1378 (myelosuppression)
aminophylline. Adjust dose.oTheoretical
▶ Interferon alfa is predicted to increase the risk of peripheral
neuropathy when given with telbivudine. Avoid.r
▶ Peginterferon alfa increases the risk of peripheral neuropathy
when given with telbivudine. Avoid.rStudy
▶ Interferons slightly increase the exposure to theophylline.
Ipilimumab → see monoclonal antibodies
Ipratropium → see TABLE 10 p. 1377 (antimuscarinics)
▶ Beta2 agonists are predicted to increase the risk of glaucoma
when given with ipratropium.oAnecdotal
Irbesartan → see angiotensin-II receptor antagonists
Irinotecan → see TABLE 15 p. 1378 (myelosuppression)
▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) are predicted to decrease the exposure
▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are
predicted to increase the risk of toxicity when given with
▶ Aprepitant is predicted to increase the exposure to
intravenous irinotecan.rTheoretical
▶ Cobicistat is predicted to increase the risk of toxicity when
given with irinotecan. Avoid.oStudy
▶ Enzalutamide is predicted to decrease the exposure to
▶ Fibrates (gemfibrozil) are predicted to increase the exposure to
irinotecan. Avoid.oTheoretical
▶ Fosaprepitant is predicted to increase the exposure to
intravenous irinotecan.rTheoretical
▶ HIV-protease inhibitors are predicted to increase the risk of
toxicity when given with irinotecan. Avoid.oStudy
▶ Idelalisib is predicted to increase the risk of toxicity when
given with irinotecan. Avoid.oStudy → Also see TABLE 15
▶ Live vaccines are predicted to increase the risk of generalised
infection (possibly life-threatening) when given with
irinotecan. Public Health England advises avoid (refer to
▶ Macrolides (clarithromycin) are predicted to increase the risk of
toxicity when given with irinotecan. Avoid.oStudy
▶ Mitotane is predicted to decrease the exposure to irinotecan.
Avoid.rStudy → Also see TABLE 15 p. 1378
is predicted to increase the exposure to irinotecan.
▶ Irinotecan is predicted to decrease the effects of
neuromuscular blocking drugs, non-depolarising
.o ▶ Pitolisant is predicted to decrease the exposure to irinotecan.
▶ Rifampicin is predicted to decrease the exposure to irinotecan.
▶ Rolapitant is predicted to increase the exposure to irinotecan.
▶ St John’s Wort slightly decreases the exposure to irinotecan.
▶ Irinotecan is predicted to increase the risk of prolonged
neuromuscular blockade when given with
ferric carboxymaltose .iron dextran .iron isomaltoside 1000 .iron
sucrose. ▶ Chloramphenicol decreases the efficacy of intravenous iron
should be taken 1 hour before or 2 hours after
▶ Iron (oral) decrease the exposure to bictegravir. Bictegravir
should be taken 2 hours before iron (oral).oStudy
▶ Iron (oral) is predicted to decrease the absorption of oral
bisphosphonates (ibandronic acid). Avoid iron (oral) for at least
6 hours before or 1 hour after
ibandronic acid.o ▶ Iron (oral) decreases the absorption of bisphosphonates
. Separate administration by at least 2 hours.
▶ Iron (oral) decreases the absorption of bisphosphonates (sodium
clodronate). Avoid iron (oral) for 2 hours before or 1 hour after
▶ Calcium salts (calcium carbonate) decrease the absorption of
iron (oral). Calcium carbonate should be taken 1 hour before or
2 hours after iron (oral).oStudy
is predicted to decrease the exposure to carbidopa.
BNF 78 Imatinib — Iron (oral) 1473
decreases the efficacy of oral iron (oral).
▶ Iron (oral) decreases the absorption of dolutegravir.
Dolutegravir should be taken 2 hours before or 6 hours after
▶ Iron (oral) is predicted to decrease the absorption of
eltrombopag. Eltrombopag should be taken 2 hours before or
4 hours after iron (oral).rTheoretical
▶ Iron (oral) is predicted to decrease the absorption of
. Separate administration by at least 2 hours.
decreases the absorption of levodopa.o ▶ Iron (oral) decreases the effects of methyldopa.oStudy
▶ Iron (oral) is predicted to decrease the absorption of
penicillamine. Separate administration by at least 2 hours.
▶ Iron (oral) decreases the exposure to quinolones. Separate
administration by at least 2 hours.oStudy
▶ Iron (oral) decreases the absorption of tetracyclines.
should be taken 2 to 3 hours after iron (oral).
▶ Iron (oral) decreases the absorption of thyroid hormones
. Separate administration by at least 4 hours.
potentially decreases the absorption of iron (oral).
▶ Zinc is predicted to decrease the efficacy of iron (oral) and iron
is predicted to decrease the efficacy of zinc.o
deferasirox . desferrioxamine . dexrazoxane. ▶ Deferasirox is predicted to increase the exposure to
aminophylline. Avoid.oTheoretical
▶ Antacids (aluminium hydroxide) are predicted to decrease the
exposure to deferasirox. Avoid.oTheoretical
▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) are predicted to decrease the exposure
deferasirox. Monitor serum ferritin and adjust dose.
▶ Ascorbic acid is predicted to increase the risk of cardiovascular
side-effects when given with desferrioxamine.r
▶ Aspirin (high-dose) is predicted to increase the risk of
gastrointestinal bleeds when given with deferasirox.r
▶ Bisphosphonates are predicted to increase the risk of
gastrointestinal bleeding when given with
▶ Deferasirox is predicted to increase the exposure to clozapine.
▶ Corticosteroids are predicted to increase the risk of
gastrointestinal bleeding when given with
▶ HIV-protease inhibitors (ritonavir) are predicted to decrease the
exposure to deferasirox. Monitor serum ferritin and adjust
▶ Live vaccines are predicted to increase the risk of generalised
infection (possibly life-threatening) when given with
dexrazoxane. Avoid.rTheoretical
▶ NSAIDs are predicted to increase the risk of gastrointestinal
bleeding when given with deferasirox.rTheoretical
▶ Deferasirox moderately increases the exposure to repaglinide.
No comments:
Post a Comment
اكتب تعليق حول الموضوع